Healthcare & Biotech

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 19, 2025 - Henry Schein One says adoption of its cloud-native Dentrix Ascend platform is accelerating as dental groups and DSOs move away from legacy practice management systems to standardize operations, reduce administrative friction, and embed AI into everyday workflows.

Cloud migration becomes a scaling decision, not an IT project
Across U.S. dentistry, consolidation and multi-location growth are forcing operators to treat practice management software as core infrastructure. Henry Schein One reported that nearly 600 practices migrated from alternative systems to Ascend over the past 12 months, adding to the broader Dentrix customer base of more than 48,000 practices using Dentrix technology for clinical, operational, and financial workflows. The company also said monthly Ascend installations more than doubled year over year as practices transitioned away from legacy setups.

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that Kintara's REM-001 clinical trial in ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety, a contractual milestone that is expected to trigger distribution of TuHURA common stock to eligible contingent value right (CVR) holders.

SHERIDAN, WYOMING - December 11, 2025 - The FDA's first use of its new Commissioner's National Priority Voucher (CNPV) has gone not to a cutting-edge biologic, but to a decades-old extended-release antibiotic, Augmentin XR-sending a clear signal that domestic manufacturing and supply resilience are now front-and-center regulatory priorities for the U.S. pharmaceutical industry.

A New Fast-Track Tool Aimed at Supply Chain Security

Launched in June, the CNPV program promises to compress review timelines from the usual 10-12 months to as little as 1-2 months for drugs that align with U.S. "national priorities," such as strengthening domestic production or addressing systemic shortages. The first approval under this framework went to USAntibiotics' Augmentin XR after the FDA completed its review in "just two months," focusing heavily on quality, manufacturing and facility assessments rather than new clinical data.

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.